OUR MISSION
To be a world leader in liquid biopsy and artificial intelligence for early detection of cancers and other diseases to improve survival and quality of life.
CHIEF EXECUTIVE OFFICER
Prof. Matthew J Baker
Inventor with 20+ years’ experience in the field of clinical spectroscopy. Top 6 KPMG Best British Tech Pioneers (2020), Fellowship of the Society for Applied Spectroscopy (2020), Top 40 under 40 Analytical Scientists (2018), RSC Harrison Meldola Prize (2017) and Emerging Leader in Molecular Spectroscopy (2016). Senior Lecturer and Reader at University of Strathclyde from 2014 - 2020. Professor of Early Diagnostics, School of Medicine, University of Central Lancashire.
CHIEF TECHNICAL OFFICER
Dr David S Palmer
20+ years' experience in the field of data analysis and machine learning. Computational chemist, leading the design and development of the Dxcover diagnostic algorithms. Reader in Chemistry at the University of Strathclyde.
​
​
​​
​
​
FINANCE DIRECTOR
John Duncan
A Chartered Accountant with 15+ years' experience gained in business financing through private equity and VC investments.
​
​
​
​
​​
​
​
HEAD OF DEVELOPMENT
Dr Holly J Butler
12+ years' experience in the clinical spectroscopy field. 'Young Entrepreneur' of the year winner, 2017 – Scottish Women's Awards 'Women in Innovation' winner, 2017 – Global Game Changers Awards. Experienced researcher in biophotonics and infrared analysis with research positions at Lancaster University and University of Strathclyde. Current MBA candidate at University of Strathclyde.​​​
OPERATIONS DIRECTOR
Dr David Eustace
13+ years' experience in regulated diagnostic product development and medical device production in both start-up and multinational environments, most recently as Operations Director at Bruker Daltonics Microbiology and Diagnostics Division.
​
​
THE BOARD
NON-EXECUTIVE CHAIRMAN
Ron A. Andrews
Ron is a highly experienced and entrepreneurial Chair. Based in the USA, he is former President & CEO of Oncocyte, Member of the ASCO Board, and President, Genetic Sciences Division, Thermo Fisher Scientific. He has extensive corporate and investor contacts, having raised over $100m in growth capital.
INVESTOR DIRECTOR
Dr Andrew McNeill
Andrew McNeill is Managing Partner at Eos Advisory. He has over 15 years’ experience in leading early-stage venture capital backed medical device and biotech companies.
NON-EXECUTIVE DIAGNOSTICS
Dr Stephen Little
Strong track record as a diagnostics leader. Former Founder & CEO of DxS (sold to Qiagen for $130M), former R&D Manager Astra Zeneca Diagnostics, and current Vice Chairman at Yourgene Health.
​
INVESTOR DIRECTOR
Professor David Onions
Representing Norcliffe Capital Limited, Prof Onions has extensive experience in growing and commercializing businesses in the Life Sciences and Biotech sector.
SCIENTIFIC ADVISORY BOARD
READER & HONORARY CONSULTANT NEUROSURGEON
Dr Paul Brennan, MB BChir PhD FRSC (SN)
Reader and Consultant Neurosurgeon at the University of Edinburgh and NHS Lothian. Strong track record leading clinical trials and laboratory research, with major focus on brain tumors. Experience as med-tech medical advisor, and founder of university spin-out eoSurgical Ltd providing surgical simulation training around the world.